Compare Innovative Industrial Properties Inc (IIPR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Innovative Industrial Properties Inc vs Viatris Inc — how do they compare? Innovative Industrial Properties Inc trades at $62.11 (market cap $1.83B), while Viatris Inc trades at $17.05 (market cap $20.50B). The key difference: Viatris Inc is far larger — about 11.2× Innovative Industrial Properties Inc's market cap, and Innovative Industrial Properties Inc pays the higher dividend (12.01%). Which is the better fit depends on your goals.
| IIPR | VTRS | |
|---|---|---|
Market Cap | $1.83B | $20.50B |
Sector | Real Estate | Health |
52-Week High | $64.67 | $17.59 |
52-Week Low | $44.58 | $8.74 |
Enterprise Value | $2.22B | $32.71B |
Dividend Yield | 12.01% | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IIPR trades at $63.25, down 1.89% today, with a bullish technical signal from moving averages. The REIT shows strong profitability with 88.46% gross margins and 45.58% net income margin, though revenue declined to $266M in 2025. Recent news highlights successful debt refinancing and upcoming Q2 2026 earnings on August 3rd, with analyst consensus leaning Hold (54.55%).
The outlook remains cautious due to revenue declines and mixed earnings performance, but strong margins and recent capital structure improvements provide stability. Key risks include cannabis sector volatility and tenant credit quality, while the 9% dividend yield offers income appeal. Wall Street sentiment is neutral with balanced risk-reward.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Innovative Industrial Properties Inc
Innovative Industrial Properties Inc is a real estate investment trust engaged in the acquisition, ownership, and management of specialized industrial properties leased to state-licensed operators for their regulated medical-use cannabis facilities. It conducts its business through a traditional umbrella partnership real estate investment trust, or UPREIT structure, in which properties are owned by Operating Partnership, directly or through subsidiaries. Its property portfolio is spread across the United States.
Read more on IIPR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
